{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:42:51Z","timestamp":1773153771023,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.1016\/s0145-2126(03)00022-5","type":"journal-article","created":{"date-parts":[[2003,3,25]],"date-time":"2003-03-25T23:24:25Z","timestamp":1048634665000},"page":"893-897","source":"Crossref","is-referenced-by-count":62,"title":["Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia"],"prefix":"10.1016","volume":"27","author":[{"given":"Apostolia","family":"Tsimberidou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elihu","family":"Estey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0145-2126(03)00022-5_BIB1","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S0145-2126(03)00022-5_BIB2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg\u2122 (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB3","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood.V98.4.988","article-title":"Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin","volume":"98","author":"Linenberger","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB4","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood.V98.12.3212","article-title":"Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study","volume":"98","author":"List","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB5","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0145-2126(03)00022-5_BIB6","first-page":"520a","article-title":"Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg\u2122, CMA-676)","volume":"98","author":"Stadtmauer","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s002770000239","article-title":"Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate","volume":"80","author":"Neumeister","year":"2001","journal-title":"Ann. Hematol."},{"key":"10.1016\/S0145-2126(03)00022-5_BIB8","first-page":"202b","article-title":"Hepatic venoocclusive disease as a complication of Mylotarg\u2122 (gemtuzumab ozogamicin): The Western Pennsylvania Cancer Institute experience","volume":"98","author":"Lech","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB9","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg\u2122) therapy","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB10","first-page":"201b","article-title":"Non-fatal veno-occlusive disease in non-transplant patients after treatment of relapsed AML with Mylotarg\u2122 (gemtuzumab ozogamicin)","volume":"98","author":"Langston","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB11","first-page":"123a","article-title":"Effects of Mylotarg\u2122 (gemtuzumab ozogomycin) in combination with standard induction chemotherapy in the treatment of acute myeloid leukaemia: a feasibility study","volume":"98","author":"Kell","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB12","first-page":"199b","article-title":"Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg\u2122) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia","volume":"98","author":"DeAngelo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB13","first-page":"587a","article-title":"Sequential administration of gemtuzumab ozogamicin and intensive chemotherapy for remission induction in previously untreated patients with AML over the age of 60: Interim results of the EORTC leukemia group AML\u2014a phase II trial","volume":"98","author":"Amadori","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB14","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood.V98.13.3575","article-title":"Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts","volume":"98","author":"Estey","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/10428199309148532","article-title":"Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia","volume":"9","author":"Estey","year":"1993","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB16","first-page":"1086","article-title":"Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1\/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study","volume":"94","author":"Leith","year":"1999","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB17","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/25.7.894009","article-title":"Proof without prejudice: use of the Kolmogorov\u2013Smirnov test for the analysis of histograms from flow systems and other sources","volume":"25","author":"Young","year":"1977","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/S0145-2126(03)00022-5_BIB18","doi-asserted-by":"crossref","unstructured":"Giles FJ, Faderl S, Thomas DA, et al. A randomized phase I\/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol 2002.","DOI":"10.1200\/JCO.2003.04.023"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V88.2.756.bloodjournal882756","article-title":"A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia","volume":"88","author":"Estey","year":"1996","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/S0145-2126(03)00022-5_BIB20","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.3816\/CLM.2002.s.006","article-title":"Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg\u2122) therapy of acute myeloid leukemia","volume":"2","author":"Leopold","year":"2002","journal-title":"Clin. Lymphoma"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB21","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1182\/blood.V99.12.4343","article-title":"Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high- risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB22","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1182\/blood-2001-12-0174","article-title":"Experience with gemtuzumab ozogamycin (\u201cMylotarg\u2122\u201d) and all-trans retinoic acid in untreated acute promyelocytic leukemia","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB23","first-page":"206b","article-title":"Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg\u2122, CMA-676): relationship to hematopoietic stem cell transplantation","volume":"96","author":"Sievers","year":"2000","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/S0145-2126(03)00022-5_BIB24","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.3816\/CLM.2002.s.007","article-title":"Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg\u2122)","volume":"2","author":"McDonald","year":"2002","journal-title":"Clin. Lymphoma"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB25","first-page":"1114","article-title":"Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg\u2122 therapy","volume":"87","author":"Giles","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/S0145-2126(03)00022-5_BIB26","unstructured":"Tsimberidou A, Estey E, Cortes J, et al. Mylotarg\u2122, fludarabine, cytarabine (ara-C) and cyclosporine (MFAC) in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer, in press."},{"key":"10.1016\/S0145-2126(03)00022-5_BIB27","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1586\/14737140.2.6.630","article-title":"Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia","volume":"2","author":"Giles","year":"2002","journal-title":"Expert. Rev. Anticancer Ther."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212603000225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212603000225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T01:00:14Z","timestamp":1682470814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212603000225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["S0145212603000225"],"URL":"https:\/\/doi.org\/10.1016\/s0145-2126(03)00022-5","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2003,10]]}}}